Literature DB >> 23560502

Mutation of the GATA site in the erythroid cell-specific regulatory element of the ABO gene in a Bm subgroup individual.

Tamiko Nakajima1, Rie Sano, Yoichiro Takahashi, Rieko Kubo, Keiko Takahashi, Yoshihiko Kominato, Junichi Tsukada, Haruo Takeshita, Toshihiro Yasuda, Makoto Uchikawa, Kazumi Isa, Kenichi Ogasawara.   

Abstract

BACKGROUND: The ABO blood group is important in blood transfusion. Recently, an erythroid cell-specific regulatory element has been identified in the first intron of ABO using luciferase reporter assays with K562 cells. The erythroid cell-specific regulatory activity of the element was dependent upon GATA-1 binding. In addition, partial deletion of Intron 1 including the element was observed in genomic DNAs obtained from 111 Bm and ABm individuals, except for one, whereas the deletion was never found among 1005 individuals with the common phenotypes. STUDY DESIGN AND METHODS: In this study, further investigation was performed to reveal the underlying mechanism responsible for reduction of B antigen expression in the exceptional Bm individual. Peptide nucleic acid-clamping polymerase chain reaction was carried out to amplify the B-related allele, followed by sequence determination. Electrophoretic mobility assays and promoter assays were performed to examine whether a nucleotide substitution reduced the binding of a transcription factor and induced loss of function of the element.
RESULTS: Sequence determination revealed one point mutation of the GATA motif in the element. The electrophoretic mobility shift assays showed that the mutation abolished the binding of GATA transcription factors, and the promoter assays demonstrated complete loss of enhancer activity of the element.
CONCLUSION: These observations suggest that the mutation in the GATA motif of the erythroid-specific regulatory element may diminish the binding of GATA transcription factors and down regulate transcriptional activity of the element on the B allele, leading to reduction of B antigen expression in erythroid lineage cells of the Bm individual.
© 2013 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23560502     DOI: 10.1111/trf.12181

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

1.  Insight into GATA1 transcriptional activity through interrogation of cis elements disrupted in human erythroid disorders.

Authors:  Aoi Wakabayashi; Jacob C Ulirsch; Leif S Ludwig; Claudia Fiorini; Makiko Yasuda; Avik Choudhuri; Patrick McDonel; Leonard I Zon; Vijay G Sankaran
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-04       Impact factor: 11.205

2.  Epithelial Expression of Human ABO Blood Group Genes Is Dependent upon a Downstream Regulatory Element Functioning through an Epithelial Cell-specific Transcription Factor, Elf5.

Authors:  Rie Sano; Tamiko Nakajima; Yoichiro Takahashi; Rieko Kubo; Momoko Kobayashi; Keiko Takahashi; Haruo Takeshita; Kenichi Ogasawara; Yoshihiko Kominato
Journal:  J Biol Chem       Date:  2016-09-01       Impact factor: 5.157

3.  Genetic sequencing analysis of the A307 subgroup of ABO blood group.

Authors:  Ying Huang; Jiajin Lin; Suiyong Zhu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

4.  A cell-specific regulatory region of the human ABO blood group gene regulates the neighborhood gene encoding odorant binding protein 2B.

Authors:  Rie Sano; Yoichiro Takahashi; Haruki Fukuda; Megumi Harada; Akira Hayakawa; Takafumi Okawa; Rieko Kubo; Haruo Takeshita; Junichi Tsukada; Yoshihiko Kominato
Journal:  Sci Rep       Date:  2021-04-01       Impact factor: 4.379

5.  Analysis of the Genomic Sequence of ABO Allele Using Next-Generation Sequencing Method.

Authors:  Yanmin He; Xiaozhen Hong; Jingjing Zhang; Ji He; Faming Zhu; He Huang
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

6.  Genetic Sequencing Analysis of A307 Subgroup of ABO Blood Group.

Authors:  Ying Huang; Jiajin Lin; Suiyong Zhu
Journal:  Med Sci Monit       Date:  2015-09-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.